Monday 19 October 2026
Export NUWE’s income statement to Excel — free account
Nuwellis, Inc.
NUWE Healthcare Medical Devices
Nuwellis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.3 million, down 5.38% from fiscal 2024. In the quarter to June 2026, revenue grew 14.1%, EPS grew 98.8% and free cash flow fell 51.6%, each against the same quarter a year earlier.
0.55
0.00
0.00%
Follow NUWE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | 3 | 3 |
| (467.58%) | (382.80%) | (610.45%) | 205.50% | ||
| (225.18%) | (219.21%) | (272.69%) | (123.52%) | ||
ROIC |
(848.43%) | (449.27%) | (1,345.35%) | 0.00% | |
Return on Tangible Assets |
(404.79%) | (694.57%) | (773.48%) | (267.06%) | |
Average Days of Receivables |
50.99 | 65.89 | 64.89 | 62.57 | |
Free Cash Flow per Share |
(393.01) | (554.47) | (195.55) | (69.97) | |
Free Cash Flow |
(9.39) | (10.92) | (11.60) | (12.68) | |
Capital Expenditures |
(0.11) | (0.11) | (0.21) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(134.15%) | (294.02%) | (244.02%) | (675.49%) | |
Accounts Receivable Turnover |
6.71 | 5.14 | 5.66 | 6.58 | |
Accounts Payable Turnover |
1.49 | 1.63 | 1.46 | 0.93 | |
Inventory Turnover |
1.65 | 1.73 | 1.72 | 1.45 | |
Average Days of Payables |
291.30 | 258.26 | 292.80 | 386.91 | |
Days of Inventory on Hand |
239.00 | 221.60 | 214.44 | 232.73 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
32.55% | 32.79% | 44.36% | 46.12% | |
Selling, General and Administrative Expense of Revenue |
161.80% | 163.46% | 164.96% | 166.44% | |
Share Based Compensation of Revenue |
2.53% | 1.54% | 0.97% | 1.00% | |
Interest Coverage |
— | — | — | (0.58) | |
Operating CF/Net income |
0.56 | 0.62 | 0.60 | 1.10 | |
Depreciation/Fixed assets |
0.63 | 0.54 | 0.45 | 0.44 | |
Capex/Depreciation |
(0.42) | (0.56) | (1.27) | (1.41) | |
Revenue per Share |
341.76 | 419.80 | 147.88 | 49.74 | |
Operating CF per Share |
(388.45) | (548.73) | (192.01) | (68.79) | |
Capex per Share |
(4.56) | (5.74) | (3.54) | (1.19) | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.02 |
Columns are period end dates